FIBROSIS AND ATRIAL FIBRILLATION — МECHANISMS AND TREATMENT
https://doi.org/10.18705/1607-419X-2013-19-6-487-494
Abstract
The molecular mechanisms of atrial fibrosis, including the role of serotonin, in atrial fibrillation as well as possible therapeutic approaches are discussed.
About the Authors
O. M. Drapkina
Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Corresponding author: Sechenov First Moscow State Medical University, 8–2 Trubetskaya st., Moscow, Russia, 119991. E-mail: drapkina@bk.ru (Oksana M. Drapkina, MD, PhD, Professor at the Department of Internal Diseases Propedeutics at Sechenov First Moscow State Medical University).
I. M. Emelyanov
Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
References
1. Jacquemet V., Henriquez S. Modeling cardiac fibroblasts, their interactions with myocytes and their impact on impulse propagation // Europace. — 2007. — Vol. 9, suppl. 6. — P. vi29–vi37.
2. De Jong S., van Veen T.A., van Rijen H.V., de Bakker J.M. Fibrosis and cardiac arrhythmias // J. Cardiovasc. Pharmacol. — 2011. — Vol. 57, № 6. — P. 630–638.
3. Tanaka K., Zlochivier S., Vikstrom K. et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure Circ. Res. — 2007. — Vol. 101. — P. 839–847.
4. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? // Heart Rhythm. — 2009. — Vol. 6. — P. 848–856.
5. Friedrichs K., Baldus S., Klinke A. Fibrosis in atrial fibrillation — role of reactive species and MPO // Front. Physio. — 2012. — Vol. 3. — P. 214. doi: 10.3389/fphys.2012.00214.
6. Zeisberg E., Kalluri R. Origins of cardiac fibroblasts // Circ. Res. — 2010. — Vol. 107, № 11. — P. 1304–1312.
7. Baum J., Duffy H.S. Fibroblasts and myofibroblasts: What are we talking about // J. Cardiovasc. Pharmacol. — 2011. — Vol. 57, № 4. — P. 376–379.
8. Драпкина О.М., Емельянов А.В. Предсердный фиброз — морфологическая основа фибрилляции предсердий // Рациональная фармакотерапия в кардиологии. — 2013. — Т. 9, № 4. — C. 417–419. / Drapkina O.M., Emelyanov A.V. Atrial fibrosis is a morphological basis of atrial fibrillation // Rational Pharmacotherapy in Cardiology [Ratsionalnaya Farmakoterapiya v Kardiologii]. — 2013. — Vol. 9, № 4. — P. 417–419 [Russian].
9. Vasquez C., Morley G. The origin and arrhythmogenic potential of fibroblasts in cardiac disease // J. Cardiovasc. Transl. Res. — 2012. — Vol. 5, № 6. — P. 760–767.
10. Yue L., Xie J., Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation // Cardiovasc. Res. — 2011. — Vol. 89, № 4. — P. 744–753.
11. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation // J. Am. Coll. Cardiol. — 2008. — Vol. 51, № 8. — P. 802–809.
12. López B., González A., Querejeta R., Díez J. The use of collage-derived serum peptides for the clinical assessment of hypertensive heart disease // J. Hypertens. — 2005. — Vol. 23, № 8. — P. 1445–1451.
13. Dees C., Akhmetshina A., Zerr P. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis // J. Exp. Med. — 2011. — Vol. 208, № 5. — P. 961–972.
14. Mann A., Oakley F. Serotonin paracrine signaling in tissue fibrosis // Biochim. Biophys. Acta. — 2013. — Vol. 1832, № 7. — P. 905–910.
15. Hanan Ahmed Galal Azzam. Thrombogenesis in atrial fibrillation / Atrial fibrillation — mechanisms and treatment. — 2013. — ISBN: 978-953-51-1023-1.
16. Чихирева Л.Н. Влияние ингибитора ангиотензинпревращающего фермента спираприла на частоту пароксизмальной мерцательной аритмии: диссертация ... кандидата медицинских наук: 14.00.06. — М., 2008. — 130 с.: ил. / Chikhireva L.N. The impact of angiotensin-converting enzyme inhibitor spirapril on the incidence of paroxysmal atrial fibrillation: PhD thesis: 14.00.96. —Moscow, 2008. — 130 p.: ill. [Russian].
17. Dąbrowski R., Szwed H. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation // Cardiol. J. — 2012. — Vol. 19, №. 3. — P. 223–229.
18. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism // J. Mol. Cell. Cardiol. — 1993. — Vol. 25, № 5. — P. 563–575.
19. Nattel S., Opie L.H. Controversies in atrial fibrillation // Lancet. — 2006. — Vol. 367, № 9506. — P. 262–272.
20. Драпкина О.М., Драпкина Ю.С. Фиброз и активность ренин-ангиотензин-альдостероновой системы. Реалии и перспективы // Артериальная гипертензия. — 2012. — Т. 18, № 5. — С. 449–458. / Drapkina O.M., Drapkina Yu.S. Fibrosis and renin-angiotensin-aldosterone system activity. Reality and future prospects // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2012. — Vol. 18, № 5. — Р. 449–458 [Russian].
21. Nattel S., Веrnstein B., Dobrev D. Atrial remodeling and atrial fibrillation: mechanism and implications // Circ. Arrhythm. Electrophysiol. — 2008. — Vol. 1, № 1. — P. 62–73.
22. Pellman J. et al. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation // J. Mol. Cell. Cardiol. — 2010. — Vol. 48, № 3. — P. 461–467.
Review
For citations:
Drapkina O.M., Emelyanov I.M. FIBROSIS AND ATRIAL FIBRILLATION — МECHANISMS AND TREATMENT. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(6):487-494. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-6-487-494
Views:
1997
Email this article 